Drugs / DISUFENTON
DISUFENTON
also known as
OKN 007 · NXY-059 · 2,4-disulfonyl pbn · 2,4-disulfonyl pnb · Cerovive · Disufenton de sodio · Disufenton sodique · DISUFENTON SODIUM · +2 more
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05561374 | Apr 2023 → May 2025 overdue | astrocytoma (excluding glioblastoma), glioblastoma, oligodendroglioma | Oblato, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03587038 | Sep 2018 → Dec 2020 overdue | glioblastoma | University of Oklahoma | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02259595 | Oct 2014 → Jan 2015 | noise induced hearing loss, sensorineural hearing loss disorder | Otologic Pharmaceutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01672463 | Dec 2012 → Jan 2023 | malignant glioma | Oblato, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03649464 | Aug 2022 → Apr 2025 | astrocytoma (excluding glioblastoma), glioblastoma, oligodendroglioma | Oblato, Inc. | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04388475 | Jun 2020 → May 2024 | brain glioblastoma | Oblato, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00075959 | Aug 2004 → Jan 2006 | intracerebral hemorrhage | AstraZeneca | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT00119626 | Jun 2003 → Feb 2005 | transient ischemic attack | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT00061022 | May 2003 → Sep 2006 | transient ischemic attack | AstraZeneca | Completed | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT05518838 | — | diffuse midline glioma, H3 K27M-mutant | Oblato, Inc. | No longer available | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DISUFENTON | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | 2,4-disulfonyl pbn | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | 2,4-disulfonyl pnb | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | Cerovive | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | Disufenton de sodio | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | Disufenton sodique | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | DISUFENTON SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | Disufenton sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111090 ↗ |
| Known as | HPN-07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259595 ↗ |
| Known as | NXY-059 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00061022 ↗ |
| Known as | OKN 007 | “400 mg OKN-007/mL in a phosphate buffer” NCT03587038 ↗ |
| Modality | Small molecule | — CHEMBL2111090 ↗ |
| Route | Intravenous | “receive a 72-hour infusion of intravenous NXY-059 or placebo within 6 hours after the onset of stroke symptoms.” PMID 17687131 ↗ Aug 2007 |